scispace - formally typeset
A

Antoine Hamel

Researcher at University of Nantes

Publications -  72
Citations -  1090

Antoine Hamel is an academic researcher from University of Nantes. The author has contributed to research in topics: Vancomycin & Medicine. The author has an hindex of 18, co-authored 66 publications receiving 924 citations. Previous affiliations of Antoine Hamel include Centre Hospitalier Universitaire de Nantes.

Papers
More filters
Journal ArticleDOI

In Vivo Efficacy of Ceftaroline (PPI-0903), a New Broad-Spectrum Cephalosporin, Compared with Linezolid and Vancomycin against Methicillin-Resistant and Vancomycin-Intermediate Staphylococcus aureus in a Rabbit Endocarditis Model

TL;DR: Using the rabbit endocarditis model, ceftaroline exhibited superior bactericidal in vivo activity against resistant S. aureus strains and appeared to be the most effective drug against a heterogeneous glycopeptide-intermediate S.aureus strain.
Journal ArticleDOI

In Vivo Efficacy of Continuous Infusion versus Intermittent Dosing of Linezolid Compared to Vancomycin in a Methicillin-Resistant Staphylococcus aureus Rabbit Endocarditis Model

TL;DR: Continuous infusion of linezolid could be an appropriate alternative to the use of glycopeptides for the treatment of severe methicillin-resistant S. aureus infections.
Journal ArticleDOI

Familial acampomelic form of campomelic dysplasia caused by a 960 kb deletion upstream of SOX9.

TL;DR: It is shown that the size of the deletion was 960 kb in the XY‐DSD child and her mother, both affected, and the deletion lying from 517 kb to 1.477 Mb upstream of SOX9 remove severalhighly conserved elements and reduce the minimum critical size and therefore the number of highly conserved sequence elements responsible for ACD.
Journal ArticleDOI

Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis

TL;DR: Ceftaroline is supported as a promising therapeutic option for the treatment of severe MRSA infections, including osteomyelitis after being the only drug to exhibit significant activity against MRSA in infected joint fluid.